Now showing items 1-1 of 1

    • Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival 

      Poli, Aurélie; Wang, Jian; Domingues, Olivia; Planagumà, Jesús; Yan, Tao; Rygh, Cecilie Brekke; Skaftnesmo, Kai Ove; Thorsen, Frits Alan; McCormack, Emmet; Hentges, François; Pedersen, Paal-Henning; Zimmer, Jacques; Enger, Per Øyvind; Chekenya, Martha (Impact Journals, 2013-09-09)
      Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet ...
      Journal article